125 related articles for article (PubMed ID: 1623873)
1. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation.
Olsson G; Allgén J; Amtorp O; Nyberg G; Parker JO
Eur Heart J; 1992 Jun; 13(6):814-7. PubMed ID: 1623873
[TBL] [Abstract][Full Text] [Related]
2. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
Waller DG
J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
Shimada K; Sunayama S; Nakazato K; Satoh H; Kusama Y; Kawakubo K; Daida H
Int Heart J; 2006 Sep; 47(5):695-705. PubMed ID: 17106140
[TBL] [Abstract][Full Text] [Related]
4. Anti-ischemic and anti-anginal effects of controlled-release and conventional isosorbide-5-mononitrate in stable angina pectoris.
Chen YH; Ding PY; Wang SP
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Oct; 61(10):577-83. PubMed ID: 9830234
[TBL] [Abstract][Full Text] [Related]
5. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
Nordlander R; Walter M
Eur Heart J; 1994 Jan; 15(1):108-13. PubMed ID: 8174569
[TBL] [Abstract][Full Text] [Related]
6. Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group.
Glasser SP
Am J Cardiol; 1997 Dec; 80(12):1546-50. PubMed ID: 9416933
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
[TBL] [Abstract][Full Text] [Related]
8. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
9. Short and long-acting oral nitrates for stable angina pectoris.
Thadani U; Lipicky RJ
Cardiovasc Drugs Ther; 1994 Aug; 8(4):611-23. PubMed ID: 7848896
[TBL] [Abstract][Full Text] [Related]
10. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.
Holmes AS; Chirkov YY; Willoughby SR; Poropat S; Pereira J; Horowitz JD
Br J Clin Pharmacol; 2005 Oct; 60(4):355-63. PubMed ID: 16187967
[TBL] [Abstract][Full Text] [Related]
11. Sustained effect of and lack of development of tolerance to controlled-release isosorbide-5-mononitrate in chronic stable angina pectoris.
Wisenberg G; Roks C; Nichol P; Goddard MD
Am J Cardiol; 1989 Sep; 64(10):569-76. PubMed ID: 2782247
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: effects on quality-of-life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group.
Zwinderman AH; Cleophas TJ; van der Sluijs H; Niemeyer MG; Buunk BP; van der Wall EE
Angiology; 1999 Dec; 50(12):963-9. PubMed ID: 10609762
[TBL] [Abstract][Full Text] [Related]
13. [Isosorbide-5-mononitrate in angina pectoris: its efficacy and absence of tolerance and rebound with an eccentric type of administration].
Schneeweiss A; Reisin L; Marmor A; Caspi A
Cardiology; 1994; 84 Suppl 1():4-12. PubMed ID: 8087823
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with Imdur in angina pectoris. A review.
Nyberg G
Eur J Clin Pharmacol; 1990; 38 Suppl 1():S65-8. PubMed ID: 1972359
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of isosorbide-5-mononitrate and isosorbide dinitrate in a slow-release form on exercise-induced myocardial ischemia.
Hennig L; Andresen D; Hennig A; Levenson B; Brüggemann T; Schröder R
J Clin Pharmacol; 1991 Jul; 31(7):636-40. PubMed ID: 1894759
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris.
Svendsen JH; Aldershvile J; Abildgaard U; Amtorp O
J Cardiovasc Pharmacol; 1989 Sep; 14(3):358-63. PubMed ID: 2476613
[TBL] [Abstract][Full Text] [Related]
17. What intervals in oral therapy of isosorbide dinitrate in various doses are sufficient to prevent nitrate tolerance?
Kośmicki M; Sadowski Z; Szwed H; Kowalik I
Med Sci Monit; 2000; 6(4):763-8. PubMed ID: 11208406
[TBL] [Abstract][Full Text] [Related]
18. When does nitrate tolerance develop? What dosages and which intervals are necessary to ensure maintained effectiveness?
Rudolph W; Dirschinger J; Reiniger G; Beyerle A; Hall D
Eur Heart J; 1988 Jan; 9 Suppl A():63-72. PubMed ID: 3137072
[TBL] [Abstract][Full Text] [Related]
19. The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study.
Nyberg G; Carlens P; Lindström E; Lundman T; Nordlander R; Rehnqvist N; Ulvenstam G; Aberg A; Aström H
Eur Heart J; 1986 Oct; 7(10):835-42. PubMed ID: 3539613
[TBL] [Abstract][Full Text] [Related]
20. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara NS; Noble S
Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
